Leadership

With a PhD in Epidemiology and a MS in Biostatistics, Dr. Aggarwal brings over 15 years of experience in industry and academia. Specializing in real-world evidence generation strategy, she excels in identifying fit-for-purpose data and designing studies that cater to the needs of various stakeholders.Her expertise spans the entire spectrum of real-world evidence generation, from early-phase and pipeline assets to post-authorization activities.

Dr. Aggarwal's hands-on experience with data from different regions such as Europe, the US, and JAPAC, including Electronic Health Records (EHR) and claims data, enables her to conduct studies on patient characteristics, disease burden, treatment patterns, healthcare utilization, as well as safety and effectiveness outcomes across a wide range of therapeutic areas.Moreover, Dr. Aggarwal is adept at leveraging Real-World Data (RWD) for regulatory-grade studies, including those crucial for drug approval and reimbursement processes, as well as post-market authorization studies. Her ability to collaborate effectively with cross-functional stakeholders, including those from clinical development, medical affairs, commercial, regulatory, health economics, payer, market access, and safety departments, sets her apart.

Additionally, Dr. Aggarwal's deep understanding of biostatistics allows her to provide valuable insights into study design and data analysis, ensuring robust evidence generation and interpretation. Her track record of successful collaborations and impactful contributions to diverse research projects underscores her strong commitment to advancing scientific knowledge and improving public health outcomes.

At Landmark, Dr. Aggarwal leads a team of epidemiologists and programmers, and remains dedicated to driving evidence-based decision-making across the healthcare industry, guiding strategic initiatives that aim to enhance patient care and treatment outcomes. Her passion for leveraging data to inform evidence-based practice and policy-making underscores her commitment to advancing the field of epidemiology and biostatistics.